Vaccine (Inactivated vaccine) · Immune activation, directed at Japanese encephalitis virus · developed by Valneva Austria GmbH
IC51 is a purified inactivated vaccine against Japanese encephalitis virus, given intramuscularly in two doses. It is studied in Japanese encephalitis and encephalitis, with the vaccine intended to stimulate immunity against the virus.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01246479 | Phase 3 | Japanese Encephalitis | Completed | VALN |
| NCT01041573 | Phase 3 | Encephalitis | Completed | VALN |
| NCT00595465 | Phase 3 | Japanese Encephalitis | Completed | VALN |
| NCT00594958 | Phase 3 | Japanese Encephalitis | Completed | VALN |
| NCT00605085 | Phase 3 | Japanese Encephalitis | Completed | VALN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
EncephalitisJapanese Encephalitis
Updated Oct 11, 2026. Something wrong or missing? Report it on the VALN page.
See VALN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VALN catalysts and pipeline →